Philips's Share Fall Reflects Past Problems, Not New Improvements -- Market Talk

Dow Jones

02/20

1200 GMT - Royal Philips's stock is undervalued due to concerns about past problems, neglecting significant improvements in operations and earnings, UBS analysts say in a note. The Dutch health-technology company's management has made a significant turnaround in recent years, completing its sleeping device recall and major personal injury litigation. It also improved profitability and reduced debt, UBS says. UBS forecasts Philips's revenue to grow at the industry average of around 5% annually from 2025-29, with EPS increasing by an average of 10% a year. Philips's share fall of 11% alongside its 2024 results is unjustifiable, making it one of the cheapest stocks in European medtech, the analysts say. As a result, UBS changes its rating of the stock to buy from neutral. Philips shares are up 0.6% at 24.23 euros. (helena.smolak@wsj.com)

(END) Dow Jones Newswires

February 20, 2025 07:00 ET (12:00 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2512096446"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512096446\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512096446?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512096446","market":"sh","top_or_hot":-1,"title":"Philips's Share Fall Reflects Past Problems, Not New Improvements -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1200 GMT - Royal Philips's stock is undervalued due to concerns about past problems, neglecting significant improvements in operations and earnings, UBS analysts say in a note. The Dutch health-technology company's management has made a significant turnaround in recent years, completing its sleeping device recall and major personal injury litigation. It also improved profitability and reduced debt, UBS says. UBS forecasts Philips's revenue to grow at the industry average of around 5% annually from 2025-29, with EPS increasing by an average of 10% a year. Philips's share fall of 11% alongside its 2024 results is unjustifiable, making it one of the cheapest stocks in European medtech, the analysts say. As a result, UBS changes its rating of the stock to buy from neutral. Philips shares are up 0.6% at 24.23 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 20, 2025 07:00 ET (12:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Philips's Share Fall Reflects Past Problems, Not New Improvements -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPhilips's Share Fall Reflects Past Problems, Not New Improvements -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-20 20:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1200 GMT - Royal Philips's stock is undervalued due to concerns about past problems, neglecting significant improvements in operations and earnings, UBS analysts say in a note. The Dutch health-technology company's management has made a significant turnaround in recent years, completing its sleeping device recall and major personal injury litigation. It also improved profitability and reduced debt, UBS says. UBS forecasts Philips's revenue to grow at the industry average of around 5% annually from 2025-29, with EPS increasing by an average of 10% a year. Philips's share fall of 11% alongside its 2024 results is unjustifiable, making it one of the cheapest stocks in European medtech, the analysts say. As a result, UBS changes its rating of the stock to buy from neutral. Philips shares are up 0.6% at 24.23 euros. (helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 20, 2025 07:00 ET (12:00 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2512096446","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512096446","pubTimestamp":1740052800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1200 GMT - Royal Philips's stock is undervalued due to concerns about past problems, neglecting significant improvements in operations and earnings, UBS analysts say in a note. The Dutch health-technology company's management has made a significant turnaround in recent years, completing its sleeping device recall and major personal injury litigation. It also improved profitability and reduced debt, UBS says. UBS forecasts Philips's revenue to grow at the industry average of around 5% annually from 2025-29, with EPS increasing by an average of 10% a year. Philips's share fall of 11% alongside its 2024 results is unjustifiable, making it one of the cheapest stocks in European medtech, the analysts say. As a result, UBS changes its rating of the stock to buy from neutral. Philips shares are up 0.6% at 24.23 euros. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","PHG":"飞利浦","BK4585":"ETF&股票定投概念","BK4082":"医疗保健设备"},"translate_title":"飞利浦股价下跌反映了过去的问题，而不是新的改进——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PHG":0.9},"content_text":"1200 GMT - Royal Philips's stock is undervalued due to concerns about past problems, neglecting significant improvements in operations and earnings, UBS analysts say in a note. The Dutch health-technology company's management has made a significant turnaround in recent years, completing its sleeping device recall and major personal injury litigation. It also improved profitability and reduced debt, UBS says. UBS forecasts Philips's revenue to grow at the industry average of around 5% annually from 2025-29, with EPS increasing by an average of 10% a year. Philips's share fall of 11% alongside its 2024 results is unjustifiable, making it one of the cheapest stocks in European medtech, the analysts say. As a result, UBS changes its rating of the stock to buy from neutral. Philips shares are up 0.6% at 24.23 euros. (helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2025 07:00 ET (12:00 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}